Researchers at the University of California, Irvine (UC Irvine) have discovered specific biomarkers that will enable innovations in diagnosis, prognosis, monitoring, and therapy of PWS and other related syndromes.
Port wine stain (PWS) involves vascular malformation of human skin. In fact, it has been reported that 3-5 children out of 1,000 live births may become affected. The current treatment of choice is PDL therapy to treat the blood vessels. However, PDL therapy is limited because the degree of PWS blanching post-PDL can be unpredictable and variable. It is difficult to achieve complete blanching due to recurrence of blood vessels in the treatment area post-PDL therapy. In fact, less than 10% of the patients achieve complete blanching.
UC Irvine researchers have invented a novel way to address the shortcomings of conventional PWS therapy. The UCI invention uses biomarkers specifically found on endothelial cells and exosomes. As such, the biomarkers provide a way to monitor the progression of PWS and related syndromes as well as the prognosis of treatment post-therapy.
Technology resides in the initial stages characterizing the utility of the biomarkers.